Phase IIIb study of durvalumab plus platinumeetoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results

被引：3

作者：

Casado, M. D. Isla ^{[1
]}

Arriola, E. ^{[2
]}

Garcia-Campelo, M. R. ^{[3
]}

Tain, P. Diz ^{[4
]}

Blanco, C. Marti ^{[5
]}

Piqueras, M. M. Lopez-Brea ^{[6
]}

Vega, A. L. Moreno ^{[7
]}

Mateos, L. A. Leon ^{[8
]}

Rodriguez, J. M. Oramas ^{[9
]}

Calderon, V. Gutierrez ^{[10
]}

Majem, M. ^{[11
]}

Hernandez, A. Sanchez ^{[12
]}

Aguado, C. ^{[13
]}

Cabellos, R. Alvarez ^{[14
]}

Ciriquian, J. L. Marti ^{[15
]}

Paul, A. Moreno ^{[16
]}

Perez, J. L. Firvida ^{[17
]}

Mellen, A. Callejo ^{[18
]}

Baez, L. ^{[18
]}

Paz-Ares, L. ^{[19
]}

机构：

[1] Hosp Clin Univ Lozano Blesa, Med Oncol Dept, Zaragoza, Spain

[2] Hosp Mar, Dept Med Oncol, Parc Salut Mar, Barcelona, Spain

[3] CHUAC Complexo Hosp Univ A Coruna, Dept Med Oncol, La Coruna, Spain

[4] Hosp Leon, Complejo Asistencial Univ Leon, Dept Med Oncol, Leon, Spain

[5] Hosp Univ Sant Joan Reus, Med Oncol, Reus, Spain

[6] HUMV Hosp Univ Marques Valdecilla, Med oncol, Santander, Spain

[7] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain

[8] CHUS Complejo Hosp Univ Santiago de Compostela, Med Oncol, Santiago De Compostela, Spain

[9] Hosp Univ Canarias, Med Oncol, Santa Cruz De Tenerife, Canary Islands, Spain

[10] Hosp Reg Univ Malaga Carlos Haya, Med oncol, Malaga, Spain

[11] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain

[12] Consorcio Hosp Prov Castellon, Dept Med Oncol, Castellon De La Plana, Spain

[13] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain

[14] Hosp Virgen Salud, Oncol Med, Toledo, Spain

[15] Hosp Gen Univ Alicante, Med Oncol, Alicante, Spain

[16] Hosp Galdakao Usansolo, Med Oncol, Galdakao, Spain

[17] Ctr Med El Carmen, Med Oncol, Orense, Spain

[18] AstraZeneca Farmaceut Spain S A, Med Dept, Madrid, Spain

[19] Hosp Univ 12 Octubre, Med Oncol Dept, Edificio Matern 2a planta, Madrid, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1224

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1993P

引用

页码：S1063 / S1063

页数：1

共 50 条

[31] Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer
Chen, Dawei
Gao, Aiqin
Zou, Bing
Huang, Wei
Shao, Qian
Meng, Xiangjiao
Zhang, Pinliang
Tang, Xiaoyong
Hu, Xudong
Zhang, Yan
Guo, Jun
Zhao, Wei
Fu, Lei
Zhao, Changhong
Yuan, Jiajia
Yu, Jinming
Wang, Linlin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[32] Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
Zhu, Youwen
Liu, Kun
Qin, Qun
Zhu, Hong
FRONTIERS IN IMMUNOLOGY, 2023, 13
[33] Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
Lan Wang
Haiyan Lou
Bo Li
Jun Li
Yun-Mei Yang
Investigational New Drugs, 2022, 40 : 151 - 156
[34] Clinicopathological Features and First-Line Treatment Outcomes of Geriatric Patients With Extensive-Stage Small Cell Lung Cancer: A Multicenter Study
Ilhan, Aysegul
Gurler, Fatih
Yilmaz, Funda
Seyran, Erdogan
Bastug, Vural
Gorgulu, Bugra
Eraslan, Emrah
Yildirim, Ozgen Ahmet
Yazici, Ozan
Oksuzoglu, Omur Berna Cakmak
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
[35] Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
Wang, Lan
Lou, Haiyan
Li, Bo
Li, Jun
Yang, Yun-Mei
INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 151 - 156
[36] Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer The Phase 3 EXTENTORCH Randomized Clinical Trial
Cheng, Ying
Zhang, Wei
Wu, Lin
Zhou, Caicun
Wang, Donglin
Xia, Bing
Bi, Minghong
Fu, Xiuhua
Li, Chong
Lv, Dongqing
Zhao, Yanqiu
Chen, Gongyan
Yi, Tienan
Huang, Jianan
Li, Min
Yang, Runxiang
Huang, Xiaoping
Wang, Ye
Zhang, Mingjun
Pan, Yueyin
Sun, Yilan
Hu, Sheng
Zhang, Xiqin
Zhou, Min
Fang, Jian
Jin, Faguang
Liu, Yunpeng
Li, Yinyin
Zhang, Zhihong
Hu, Jie
Liu, Laiyu
Wang, Rui
Li, Yan
Gu, Kangsheng
Ding, Cuimin
Fan, Qingxia
Zhang, Guojun
Chen, Yongxing
Jiang, Liyan
Zheng, Wei-E.
Chen, Shaoshui
Huang, Cheng
Han, Zhigang
Yang, Hong
Wang, Jianfang
Wang, Baocheng
Wu, Huita
Bao, Yongxing
Li, Manxiang
Luo, Xianming
JAMA ONCOLOGY, 2025, 11 (01) : 16 - 25
[37] Biomarker Analysis of Camrelizumab Plus Nab-paclitaxel and Carboplatin as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
Yu, J.
Zhou, C.
Wang, L.
Jiang, T.
Xiong, A.
Yuan, J.
Shi, W.
Ren, S.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S209 - S210
[38] Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial
Deng, Pengbo
Hu, Chengping
Chen, Cen
Cao, Liming
Gu, Qihua
An, Jian
Qin, Ling
Li, Min
He, Baimei
Jiang, Juan
Yang, Huaping
CANCER MEDICINE, 2022, 11 (19): : 3563 - 3571
[39] Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
Zhou, Fei
Zhao, Wencheng
Gong, Xiaomei
Ren, Shengxiang
Su, Chunxia
Jiang, Tao
Zhou, Caicun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[40] First-Line Envafolimab plus Carboplatin-etoposide in Extensive-Stage Small-Cell Lung Cancer: a Single-Arm Phase II Study
Sun, S.
Zhao, X.
Zhang, J.
Zhang, X.
Han, Q.
Yan, X.
Zhu, Y.
Wang, J.
Jiao, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S371 - S371

← 1 2 3 4 5 →